Business Context and Reporting Period
Company: Outlook Therapeutics, Inc. (OTLK)
Filing Type: Form 8-K (Current Report)
Date of Report: September 16, 2026
Reporting Period: Event date of September 16, 2026
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a pricing event.
Material Changes
On September 16, 2026, the company established the wholesale acquisition cost (WAC) for its product LYTENAVA in the United States at $485 per vial.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items beyond the pricing announcement.
Investor Verification Checklist
- Verify the final retail pricing and reimbursement rates for LYTENAVA following the $485 WAC announcement.
- Confirm the commercial launch timeline and distribution strategy for LYTENAVA in the U.S. market.
- Review subsequent filings for any updates on sales volume or revenue recognition related to this pricing structure.